Core Insights - MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing invariant natural killer T (iNKT) cell therapies and will present at the 10th Annual CAR-TCR Summit [1][2] Company Overview - MiNK Therapeutics is pioneering allogeneic iNKT cell therapies and precision-targeted immune technologies aimed at restoring immune balance and driving cytotoxic immune responses across various diseases [5] - The company's lead asset, agenT-797, is currently in clinical development for treating graft-versus-host disease (GvHD), solid tumors, and critical pulmonary immune collapse [5] - MiNK is also advancing a pipeline of T cell receptor (TCR)-based therapies and neoantigen discovery tools for tumor- and tissue-specific immune activation [5] Industry Context - The CAR-TCR Summit is a significant global forum for cell therapy, gathering over 800 stakeholders, including executives, scientists, investors, and regulators [4] - The summit features over 100 speakers and multiple content tracks, showcasing breakthroughs in CAR-T, TCR, and iNKT cell therapies across oncology and autoimmune diseases [4] - Dr. Jennifer Buell, CEO of MiNK, will discuss the potential of iNKT cells in restoring immune balance in diseases with limited treatment options [3][2]